A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.
Advanced Solid Tumor
DRUG: SPH6516 tablets
MTD（Maximum tolerated dose）, Maximum tolerated dose, Approximately 2 years
Incidence of Treatment-Emergent Adverse Events, Adverse event type, incidence, duration, Approximately 2 years|Peak Plasma Concentration (Cmax）, PK (Pharmacokinetics), Approximately 2 years|Peak time（Tmax）, PK (Pharmacokinetics), Approximately 2 years|Area under the plasma concentration versus time curve (AUC), PK (Pharmacokinetics), Approximately 2 years|half-life（T1/2）, PK (Pharmacokinetics), Approximately 2 years|Objective response rate(ORR), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1, Approximately 2 years|Progression-free survival (PFS), The interval between the date of the first dose of trial treatment until first documentation of disease progression or death, whichever occurs first., Approximately 2 years
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.